A physician orders an MRI for a Medicare Advantage enrollee with worsening back pain. Before the scan happens, the insurer has to approve it. That approval process, known as prior authorization, can stretch into days or weeks of phone calls, faxes, and paperwork. Sometimes the answer is no, even when the service meets Medicare’s own coverage rules.
For the more than 33 million Americans enrolled in Medicare Advantage plans, prior authorization is one of the most common friction points in their health care. Now a new Senate bill is taking direct aim at the system. Sen. Sheldon Whitehouse (D-R.I.) introduced S. 3762 on February 3, 2026, proposing a standardized prior authorization framework across every MA plan and giving the Centers for Medicare and Medicaid Services the authority to audit how insurers handle approval requests. The bill, referred to the Senate Finance Committee, would go further than any existing federal rule in regulating the gatekeeping process that has drawn years of complaints from patients and doctors, according to the official congressional record.
Three changes enrollees would notice
The bill attacks the prior authorization problem from three directions.
First, it would require every MA plan to follow a single, uniform set of rules when processing prior authorization requests. Right now, each insurer sets its own procedures, which means a doctor’s office treating patients across multiple plans may juggle dozens of different submission forms, timelines, and criteria. Standardization would replace that patchwork.
Second, S. 3762 would give CMS the power to audit insurers for compliance. Under current law, no comparable enforcement mechanism exists specifically for prior authorization practices in MA plans.
Third, the bill would exempt providers who already participate in certain value-based care arrangements where they share financial responsibility for patient outcomes. The logic: those physicians already have a built-in incentive to avoid ordering unnecessary services, so requiring insurer pre-approval on top of that adds cost without clear benefit. Practices outside those arrangements would still face prior authorization, but under the new standardized and auditable rules.
That exemption carries a strategic purpose. The federal government has spent years trying to move more doctors and health systems into value-based contracts. Relieving those providers of prior authorization burdens could accelerate the shift by making such arrangements more attractive.
The scale of the problem
The complaints driving this bill are backed by federal data. A 2022 report from the HHS Office of Inspector General, the most recent comprehensive federal review of the issue, found that 13 percent of prior authorization denials in Medicare Advantage were for services that actually met Medicare’s coverage criteria. In other words, insurers were blocking care that traditional Medicare would have covered.
The American Medical Association has reinforced those findings through annual physician surveys. In its most recent data, the AMA reported that 94 percent of physicians said prior authorization delayed necessary care, and nearly one in three said the process had led to a serious adverse event for a patient. Those numbers have remained stubbornly high year after year.
Where federal regulation already stands
S. 3762 is not the government’s first move on prior authorization. CMS has been pursuing its own reforms through rulemaking, though with a different focus. The agency’s Interoperability and Prior Authorization Final Rule (CMS-0057-F), published in the Federal Register in February 2024, centered on technology: requiring certain payers to build digital systems that let providers submit requests electronically, track decisions in real time, and receive detailed explanations when requests are denied. A CMS fact sheet on the rule describes shortened decision timeframes and new transparency requirements.
CMS has also proposed a 2026 rule that would extend electronic prior authorization requirements to prescription drugs, adopt modern data-sharing standards, compress decision windows further, and increase transparency. These regulatory efforts target the mechanics of the process: how fast decisions are made, how they are communicated, and what technology supports them.
What the Whitehouse bill adds is an enforcement and standardization layer on top of that infrastructure. CMS rules tell insurers to build better systems and respond faster. S. 3762 would tell them to follow the same playbook and prove it through audits. The two tracks are running in parallel, and together they point toward a future where prior authorization is both more automated and more closely supervised.
Financial pressures complicating the debate
Any new requirement on MA plans arrives during a period of financial strain for insurers. The independent Medicare Payment Advisory Commission, in its March 2026 report to Congress, detailed how Medicare pays MA plans above what the same care would cost under traditional Medicare, driven partly by aggressive diagnosis coding that inflates risk-adjusted payments. The 2026 CMS Advance Notice confirmed that the phase-in of an updated risk adjustment model for MA completes this year, which is expected to squeeze some plan margins.
Those financial dynamics shape the political fight. If insurers view standardized rules and CMS audits as adding compliance costs without offsetting savings, industry opposition will be intense. If lawmakers can argue the incremental burden is modest, particularly for plans that have already invested in the digital infrastructure CMS requires, the calculus could shift. As of May 2026, neither major insurers nor industry trade groups such as AHIP have made public statements on S. 3762.
Open questions that could determine the bill’s fate
Several significant unknowns hang over the legislation. No Congressional Budget Office score has been published, leaving unclear how much the audit and standardization requirements would cost to implement or whether they would generate savings by reducing inappropriate denials and the downstream medical complications that delayed care can cause.
CMS has not publicly responded to the bill’s specific provisions. Whether the agency views the legislation as complementary to its own reforms or as congressional overreach into territory it prefers to manage through regulation will influence how closely agency staff engage during any markup or hearing.
The provider community could fracture along predictable lines. Large health systems already in value-based contracts might welcome the exemption as a competitive edge, while smaller independent practices that lack such arrangements may push for broader relief from prior authorization regardless of their payment model. Major hospital associations and physician groups have not yet taken formal positions.
Prior authorization reform has attracted bipartisan interest in past sessions. The Improving Seniors’ Timely Access to Care Act, a similar effort, passed the House in 2022 but stalled in the Senate. Whitehouse has introduced versions of this legislation before without reaching a floor vote. The current regulatory momentum from CMS and growing public frustration with MA plan denials may create a more favorable environment, but competing priorities around Medicare spending, drug pricing, and broader budget negotiations could sideline the measure again. Without visible co-sponsorship from key Finance Committee members or a scheduled hearing, S. 3762 remains at an early legislative stage.
What enrollees should know right now
For people currently enrolled in Medicare Advantage, the practical impact of S. 3762 is not yet real. The bill has not advanced past committee referral, and even if it does, implementation would take time.
But enrollees facing prior authorization delays or denials today are not without options. Medicare Advantage plans are required to provide a written explanation when they deny a request, and enrollees have the right to appeal. If the plan upholds its denial on internal appeal, the case moves to an independent review organization. CMS data shows that a significant share of denials are overturned at some stage of the appeals process, which suggests the system’s initial gatekeeping is often more restrictive than the rules warrant.
The broader trajectory is clear. Between S. 3762, CMS rulemaking, and sustained pressure from physician organizations and patient advocates, the federal government is moving toward tighter oversight of how MA insurers approve and deny care. Whether this particular bill becomes law or simply adds momentum that shapes future regulation, the debate over prior authorization is no longer a side issue in Medicare policy. For millions of enrollees, it is the issue that determines whether the coverage they chose actually delivers the care they need.
